www.sagerx.com Open in urlscan Pro
18.245.31.102  Public Scan

Form analysis
2 forms found in the DOM

GET /search

<form class="site-header-search-form st-search" method="get" id="header-search-form-mobile" action="/search" data-st-enginekey="rCVfUDtLLn5w_JjqTvUk">
  <div class="l-site-header-search-form">
    <label class="searchLabel" for="st-search-input">Search</label>
    <input class="site-header-search-input form-control st-default-search-input st-input" placeholder="Search" type="search" value="" name="s" id="st-search-input" autocomplete="off">
    <button class="site-header-search-btn" type="submit">
      <span class="sr-only">Search</span>
      <i class="fas fa-search" aria-hidden="true"></i>
    </button>
  </div>
</form>

GET /search

<form method="get" class="site-header-search-form st-search" id="header-search-form" action="/search" data-st-enginekey="rCVfUDtLLn5w_JjqTvUk">
  <div class="l-site-header-search-form">
    <label class="searchLabel" for="st-search-input2">Search</label>
    <input class="site-header-search-input form-control st-default-search-input st-input" placeholder="Search" type="search" id="st-search-input2" autocomplete="off">
    <button class="site-header-search-btn" type="submit">
      <span class="sr-only">Search</span>
      <i class="far fa-search" aria-hidden="true"></i>
    </button>
    <button class="close-search" type="button">
      <i class="fal fa-times" aria-hidden="true" title="close search box"></i><span class="sr-only">close search box</span>
      <span class="close-search-text">Close Search</span>
    </button>
  </div>
</form>

Text Content

NOW AVAILABLE:

ZURZUVAE®
(ZURANOLONE) CIV, FOR
THE TREATMENT OF WOMEN
WITH POSTPARTUM
DEPRESSION

U.S. PRESCRIBING INFORMATION

U.S. MEDICATION GUIDE

LEARN MORE


SEEING THE BRAIN DIFFERENTLY
MAKES A WORLD OF DIFFERENCE

Learn More About Our Approach

Previous Next
Previous Next
 1. now available
 2. hero 2


PATIENTS & CARE PARTNERS PUTTING PATIENTS AND THEIR FAMILIES FIRST

We are rethinking care and how it is delivered to help patients and families
impacted by brain health disorders.

 * Postpartum Depression
 * Patient Advocacy Programs

See our resources for patients



NEWS THE LATEST FROM SAGE


PRESS RELEASES & STATEMENTS

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights
Pipeline and Business Progress




EVENTS & PRESENTATIONS

Sage Therapeutics Q2 2024 Financial Results Conference Call




SAGE MEDICAL HUB

Search our library of medical resources, contact a Medical Science Liaison,
submit a medical inquiry, and more. For US Healthcare Professionals.



See All News


PIPELINE ADVANCING A LEADING BRAIN HEALTH PORTFOLIO

Compound
Target Indications
Phase 1
Phase 2
Phase 3
Status
Postpartum Depression Commercial Products
ZURZUVAE®*
(zuranolone) CIV
 * Postpartum Depression

Marketed
Marketed
ZULRESSO®
(brexanolone) CIV injection
 * Postpartum Depression

Marketed
Marketed
Pipeline
Zuranolone*
(SAGE-217)
 * Major Depressive Disorder**

IN PHASE 3
IN PHASE 3
Dalzanemdor
(SAGE-718)
 * Huntington’s Disease Cognitive Impairment

IN PHASE 2
IN PHASE 2

--------------------------------------------------------------------------------

 * Alzheimer’s Disease Mild Cognitive Impairment and Mild Dementia

IN PHASE 2
IN PHASE 2
Programs In Evaluation
 * SAGE-324***
   GABA Hypofunction
 * SAGE-689
   Acute GABA Hypofunction
 * SAGE-421
   NMDA Hypofunction
 * SAGE-319
   GABA Hypofunction

*Collaboration Partners: Biogen Inc. and Shionogi for zuranolone
**The FDA issued a CRL on August 4, 2023, related to the NDA for the treatment
of adults with MDD stating that the application did not provide substantial
evidence of effectiveness to support the approval of zuranolone for the
treatment of MDD and that an additional study or studies will be needed. No
Phase 3 trials are currently ongoing.
***On July 24, 2024, Sage and Biogen announced discontinuation of clinical
development of SAGE-324 in ET. The companies are evaluating next steps, if any,
for other potential indications.

Please refer to the U.S. Prescribing Information for ZULRESSO and the U.S.
Prescribing Information for ZURZUVAE
Safety and efficacy for investigational uses or compounds have not been
established.

LEARN MORE ABOUT OUR PROGRAMS AND RESEARCH

We have recently updated our Privacy Policy to include information regarding the
cookies we collect. By continuing to use this website you agree to our Privacy
Policy and Terms of Use .
ACCEPT

Menu
   
 * Patients & Care Partners
      
    * Patients & Care Partners
    * Patient Advocacy
    * Patient Advocacy Sponsorships & Grants
    * Patient Support
   
    * Main

   
 * Healthcare Providers
      
    * Healthcare Providers
    * Visit the Sage Medical Hub
   
    * Main

   
 * Our Medicines
   
 * Therapeutic Focus
      
    * Therapeutic Focus
    * A New Approach to Brain Health Disorders
    * GABA & NMDA Receptors
   
    * Main

   
 * Programs & Research
      
    * Programs & Research
    * Depression Franchise
    * Neurology Franchise
    * Neuropsychiatry Franchise
    * Pipeline
    * Clinical Trials
    * Early Access
    * Collaborations
   
    * Main

   
 * About Us
      
    * About Us
    * Mission & Values
    * Corporate Governance
    * Our Team
    * Partnering
    * Social Responsibility
    * Funding & Giving
   
    * Main

   
 * Working At Sage
 * Toggle Search Toggle Search Box

Search Search
   
 * Investors/Media
   
 * Clinical Trials
   
 * Contact Us

Search Search close search box Close Search



PATIENTS & CARE PARTNERS

 * Patient Advocacy
 * Patient Advocacy Sponsorships & Grants
 * Patient Support


HEALTHCARE PROVIDERS

 * Visit the Sage Medical Hub


OUR MEDICINES


THERAPEUTIC FOCUS

 * A New Approach to Brain Health Disorders
 * GABA & NMDA Receptors


PROGRAMS & RESEARCH

 * Depression Franchise
 * Neurology Franchise
 * Neuropsychiatry Franchise
 * Pipeline
 * Clinical Trials
 * Early Access
 * Collaborations


ABOUT US

 * Mission & Values
 * Corporate Governance
 * Our Team
 * Partnering
 * Social Responsibility
 * Funding & Giving


WORKING AT SAGE

 * Investors/Media
 * Clinical Trials
 * Contact Us

 * Facebook
 * Twitter
 * Instagram
 * LinkedIn

© 2024 Sage Therapeutics, Inc

 * Privacy Policy
 * Terms of Use
 * Community Guidelines
 * Accessibility
 * Site Map

SAGE THERAPEUTICS, ZULRESSO, and their respective logos, SAGE CENTRAL, and
ZURZUVAE are registered trademarks of Sage Therapeutics, Inc. The ZURZUVAE logo
is a trademark of Sage Therapeutics, Inc. All other trademarks referenced herein
are the property of their respective owners.

×


×



You are now leaving Sagerx.com and entering a website that is not owned or
controlled by Sage Therapeutics, Inc.

Sage Therapeutics, Inc. makes no representation as to the accuracy of the
information contained on websites it does not own or control. Sage Therapeutics,
Inc. does not recommend and does not endorse the content of any third-party
websites. Your use of third-party websites is at your own risk and subject to
the terms and conditions of use for such sites.

Continue Cancel

You are now leaving Sagerx.com, the official site for Sage Therapeutics, Inc.
This link will take you to another Sage Therapeutics, Inc. website.

Continue Cancel